We are excited to attend PBSS: Biodistribution, Target Engagement and PK/PD for Antibody/ADC/Nucleotide/Novel Protein-Based Therapeutics: Quantitative Assessment and Translation. The Pharmaceutical and BioScience Society International (PBSS) is a non-profit organization of over 20,000 participants, within the biotechnology and pharmaceutical industries, working to promote the exchange of scientific ideas and provide new learning opportunities through educational and professional development events. Join us for the workshop and visit our table during the vendor show to learn more about Biocytogen’s preclinical products and services.
What is PBSS: Biodistribution, Target Engagement and PK/PD for Antibody/ADC/Nucleotide/Novel Protein-Based Therapeutics: Quantitative Assessment and Translation?
Scientists and researchers in drug development face the challenge of predicting pharmacokinetics (PK), pharmacodynamics (PD), and target engagement in tissues that cannot be clinically sampled. This workshop will cover current modeling and experimental strategies to further examine the biodistribution of large molecule therapeutics. Topics to be discussed include PBPK modeling of antibody drug conjugates and T-cell dependent bispecifics in heme and solid tumor indications, brain delivery and biodistribution of systemically administered antibodies, and the mechanistic modelling of orally administered protein therapeutics for gut site of action. Between the talks, vendor shows will be held for exhibitors to share their research and innovations.
Event Overview
Date: January 15th, 2026
Venue: Crowne Plaza San Francisco Airport by IHG, 1177 Airport Blvd., Burlingame, CA 94010
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to meeting you in San Francisco, CA!
